Loading
Everything OnCo dates to 1966: 11 entries, 5 landmarks, 2 approvals, 2 journals founded and 1 company founded. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
11 dated entries in OnCo fall in 1966: 5 landmarks, 2 approvals, 2 journals founded, 1 company founded and 1 paper listed on a person's page.
Of those, 11 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Polycythaemia vera; chronic myeloid leukaemia refractory to busulfan (historic label). Discontinued
Remission induction and consolidation of acute non-lymphocytic leukaemias
The history entries editors wrote on cancer records: the dated turning points of each disease.
Nasopharyngeal carcinoma
Localised prostate cancer, very low and low risk
Prostate cancer
Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)
Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)
The founded year on company records.
Pune
The founded year on journal records.
Elsevier Masson
Wiley
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
JAMA: The Journal of the American Medical Association